benazepril ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 299 86541-75-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • benazepril
  • cibacen
  • benazepril hydrochloride
  • benazepril HCl
prodrug of benazeprilat inhibit angiotensin-converting enzyme (ACE) and results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion
  • Molecular weight: 424.50
  • Formula: C24H28N2O5
  • CLOGP: 1.82
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 95.94
  • ALOGS: -4.61
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
7.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 78 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.13 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 18 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
June 25, 1991 FDA US PHARMS HOLDINGS I

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 137.02 12.83 111 17686 47854 63423371
Cerebrovascular accident 127.18 12.83 154 17643 107870 63363355
Coronary artery disease 116.63 12.83 86 17711 32291 63438934
Myocardial infarction 115.29 12.83 141 17656 99752 63371473
Cardiac failure congestive 109.14 12.83 132 17665 92301 63378924
Off label use 69.18 12.83 53 17744 674409 62796816
Drug ineffective 55.61 12.83 133 17664 1044632 62426593
Maternal exposure during pregnancy 44.21 12.83 5 17792 220057 63251168
Contraindicated product administered 43.59 12.83 5 17792 217643 63253582
Transient ischaemic attack 43.02 12.83 53 17744 37700 63433525
Drug intolerance 42.00 12.83 17 17780 308644 63162581
Chest pain 41.52 12.83 144 17653 215815 63255410
Treatment failure 38.81 12.83 5 17792 199038 63272187
Dizziness 38.21 12.83 228 17569 429697 63041528
Blood pressure inadequately controlled 37.34 12.83 21 17776 4957 63466268
Renal failure 35.46 12.83 92 17705 117560 63353665
Swollen tongue 35.13 12.83 46 17751 34754 63436471
Systemic lupus erythematosus 34.71 12.83 8 17789 208910 63262315
Infusion related reaction 34.25 12.83 13 17784 245508 63225717
Glossodynia 33.67 12.83 5 17792 178871 63292354
Hand deformity 33.64 12.83 3 17794 159454 63311771
Mitral valve incompetence 33.50 12.83 34 17763 19560 63451665
Vasodilatation 32.28 12.83 15 17782 2380 63468845
Carotid artery stenosis 31.35 12.83 19 17778 5151 63466074
Product complaint 31.08 12.83 27 17770 12782 63458443
Oropharyngeal swelling 30.53 12.83 11 17786 910 63470315
Angina unstable 30.50 12.83 21 17776 7074 63464151
Oedema peripheral 30.22 12.83 119 17678 189392 63281833
Arteriosclerosis 30.21 12.83 24 17773 10042 63461183
Rhabdomyolysis 29.63 12.83 48 17749 43903 63427322
Renal tubular atrophy 28.50 12.83 10 17787 766 63470459
Completed suicide 26.98 12.83 96 17701 145577 63325648
Exposure during pregnancy 25.74 12.83 6 17791 155541 63315684
Wound 25.66 12.83 7 17790 163256 63307969
Nephrosclerosis 25.52 12.83 10 17787 1044 63470181
Emotional distress 25.36 12.83 38 17759 32511 63438714
Cardiovascular disorder 24.90 12.83 23 17774 11789 63459436
Cardiac disorder 24.59 12.83 48 17749 50768 63420457
Kounis syndrome 23.83 12.83 11 17786 1719 63469506
Renal injury 23.11 12.83 20 17777 9419 63461806
Tricuspid valve incompetence 22.53 12.83 24 17773 14597 63456628
Pericarditis 21.92 12.83 5 17792 131574 63339651
Arteriosclerosis coronary artery 21.02 12.83 18 17779 8355 63462870
Dehydration 20.84 12.83 100 17697 173254 63297971
Palpitations 20.60 12.83 74 17723 112696 63358529
Blood pressure increased 20.58 12.83 95 17702 161967 63309258
Depression 20.56 12.83 109 17688 196383 63274842
Gastrointestinal haemorrhage 20.00 12.83 59 17738 81117 63390108
Kidney fibrosis 19.96 12.83 10 17787 1871 63469354
Fear 19.37 12.83 23 17774 15743 63455482
Reaction to excipient 19.20 12.83 9 17788 1455 63469770
Swelling face 18.46 12.83 49 17748 63426 63407799
Product use issue 18.19 12.83 21 17776 220499 63250726
Hyperdynamic left ventricle 17.87 12.83 5 17792 181 63471044
Joint swelling 17.85 12.83 41 17756 327625 63143600
Gastrooesophageal reflux disease 17.67 12.83 63 17734 95576 63375649
Coronary artery occlusion 17.36 12.83 16 17781 8175 63463050
C-reactive protein increased 17.02 12.83 3 17794 94704 63376521
Keratoacanthoma 16.88 12.83 6 17791 477 63470748
Asthenia 15.97 12.83 171 17626 383433 63087792
Injury 15.96 12.83 51 17746 73196 63398029
Hyperlipidaemia 15.46 12.83 23 17774 19548 63451677
Tendon rupture 15.38 12.83 15 17782 8224 63463001
Blood urea increased 15.37 12.83 27 17770 26352 63444873
Blood glucose increased 15.33 12.83 55 17742 83701 63387524
Therapeutic product effect decreased 15.29 12.83 19 17778 193168 63278057
Peripheral vascular disorder 15.21 12.83 13 17784 6022 63465203
Vasoplegia syndrome 15.05 12.83 8 17789 1691 63469534
Discomfort 14.84 12.83 15 17782 167359 63303866
Alopecia 14.80 12.83 47 17750 337489 63133736
Cardiomegaly 14.35 12.83 21 17776 17593 63453632
Laryngeal pain 14.09 12.83 11 17786 4487 63466738
Mental status changes 14.07 12.83 33 17764 39566 63431659
Myalgia 13.79 12.83 79 17718 146450 63324775
Hiatus hernia 13.76 12.83 23 17774 21571 63449654
Anxiety 13.64 12.83 106 17691 217435 63253790
Pyrexia 13.53 12.83 77 17720 470401 63000824
Haemorrhoids 13.34 12.83 23 17774 22127 63449098
Intestinal ischaemia 12.84 12.83 13 17784 7455 63463770
Rheumatoid arthritis 12.84 12.83 33 17764 253786 63217439

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 197.49 13.20 145 14110 37229 34905447
Myocardial infarction 127.14 13.20 198 14057 120887 34821789
Coronary artery disease 107.93 13.20 115 14140 48190 34894486
Cardiac failure congestive 73.47 13.20 126 14129 83144 34859532
Cerebrovascular accident 70.49 13.20 125 14130 84686 34857990
Off label use 63.90 13.20 47 14208 419477 34523199
Oropharyngeal oedema 34.28 13.20 8 14247 92 34942584
Injury 33.89 13.20 42 14213 20645 34922031
Shock 31.71 13.20 44 14211 24135 34918541
Distributive shock 29.58 13.20 13 14242 1241 34941435
Swollen tongue 29.48 13.20 33 14222 14572 34928104
Chest pain 27.20 13.20 113 14142 126649 34816027
Emotional distress 27.05 13.20 32 14223 14994 34927682
Product complaint 26.95 13.20 21 14234 5869 34936807
Blood glucose increased 26.33 13.20 73 14182 66645 34876031
Nodular rash 23.37 13.20 6 14249 105 34942571
Lymphomatoid papulosis 19.70 13.20 6 14249 200 34942476
Neutropenia 19.62 13.20 21 14234 156757 34785919
Asthenia 19.31 13.20 168 14087 245083 34697593
Tongue oedema 18.96 13.20 13 14242 2984 34939692
Carotid artery stenosis 18.96 13.20 16 14239 5003 34937673
Blood pressure inadequately controlled 18.01 13.20 12 14243 2628 34940048
Depression 17.36 13.20 82 14173 97016 34845660
Blood gases abnormal 16.89 13.20 6 14249 326 34942350
Pancreatitis 16.79 13.20 44 14211 38847 34903829
Acute myocardial infarction 16.66 13.20 54 14201 53665 34889011
Angina unstable 16.48 13.20 22 14233 11631 34931045
General physical health deterioration 16.24 13.20 17 14238 128252 34814424
Cardiovascular disorder 15.80 13.20 20 14235 10036 34932640
Anxiety 15.66 13.20 81 14174 99347 34843329
Nephrogenic systemic fibrosis 15.61 13.20 13 14242 3992 34938684
Hyperlipidaemia 15.51 13.20 24 14231 14505 34928171
Fear 15.15 13.20 20 14235 10456 34932220
Pharyngeal oedema 14.55 13.20 15 14240 6032 34936644
Drug interaction 14.26 13.20 46 14209 225900 34716776
Lacunar infarction 14.10 13.20 11 14244 3079 34939597
Dizziness 13.85 13.20 143 14112 218378 34724298
Type 2 diabetes mellitus 13.76 13.20 24 14231 16008 34926668
Lip swelling 13.71 13.20 24 14231 16056 34926620
Product use in unapproved indication 13.33 13.20 17 14238 117482 34825194

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 287.48 12.01 218 24988 75817 79643365
Myocardial infarction 252.99 12.01 301 24905 183828 79535354
Coronary artery disease 243.67 12.01 186 25020 65288 79653894
Cerebrovascular accident 192.31 12.01 241 24965 155051 79564131
Cardiac failure congestive 159.00 12.01 210 24996 142192 79576990
Off label use 112.07 12.01 75 25131 907140 78812042
Chest pain 52.53 12.01 202 25004 282102 79437080
Transient ischaemic attack 51.59 12.01 73 25133 52622 79666560
Emotional distress 50.91 12.01 63 25143 39906 79679276
Angina unstable 50.80 12.01 42 25164 16485 79702697
Carotid artery stenosis 44.27 12.01 30 25176 8728 79710454
Product complaint 43.29 12.01 35 25171 13314 79705868
Swollen tongue 43.20 12.01 60 25146 42510 79676672
Drug intolerance 41.14 12.01 16 25190 264103 79455079
Cardiac disorder 40.81 12.01 74 25132 65683 79653499
Drug ineffective 40.04 12.01 191 25015 1080722 78638460
Cardiovascular disorder 39.83 12.01 38 25168 17987 79701195
Blood pressure inadequately controlled 38.18 12.01 24 25182 6153 79713029
Shock 37.80 12.01 57 25149 43491 79675691
Renal failure 37.50 12.01 144 25062 200824 79518358
Injury 36.89 12.01 78 25128 77418 79641764
Drug abuse 34.81 12.01 5 25201 162686 79556496
Arteriosclerosis 33.93 12.01 35 25171 18192 79700990
Acute myocardial infarction 33.77 12.01 75 25131 76961 79642221
Contraindicated product administered 33.34 12.01 5 25201 157533 79561649
Mitral valve incompetence 33.17 12.01 43 25163 28522 79690660
Treatment failure 32.65 12.01 7 25199 170479 79548703
Depression 31.58 12.01 144 25062 216646 79502536
Fear 30.18 12.01 36 25170 21950 79697232
Neutropenia 30.04 12.01 28 25178 287682 79431500
Hyperlipidaemia 29.86 12.01 39 25167 26054 79693128
Infusion related reaction 29.69 12.01 18 25188 230219 79488963
Dizziness 28.78 12.01 273 24933 526168 79193014
Peripheral vascular disorder 28.06 12.01 22 25184 8008 79711174
Arteriosclerosis coronary artery 27.52 12.01 31 25175 17785 79701397
Maternal exposure during pregnancy 27.41 12.01 5 25201 136533 79582649
Vasodilatation 26.50 12.01 15 25191 3176 79716006
Blood pressure increased 25.47 12.01 133 25073 211227 79507955
Renal injury 25.38 12.01 29 25177 16898 79702284
Oropharyngeal oedema 24.45 12.01 8 25198 438 79718744
Pyrexia 24.41 12.01 121 25085 678588 79040594
Tongue oedema 23.80 12.01 19 25187 7098 79712084
Tricuspid valve incompetence 23.39 12.01 30 25176 19682 79699500
Distributive shock 23.32 12.01 13 25193 2674 79716508
C-reactive protein increased 23.31 12.01 6 25200 129021 79590161
Anxiety 23.14 12.01 146 25060 248366 79470816
Blood glucose increased 22.77 12.01 84 25122 114891 79604291
Lacunar infarction 22.29 12.01 17 25189 5940 79713242
Ventricular hypertrophy 22.09 12.01 18 25188 6920 79712262
Rheumatoid arthritis 22.09 12.01 20 25186 208450 79510732
Nephrosclerosis 21.98 12.01 11 25195 1819 79717363
Exposure during pregnancy 21.89 12.01 3 25203 101129 79618053
Asthenia 21.65 12.01 252 24954 511437 79207745
Systemic lupus erythematosus 21.19 12.01 6 25200 121143 79598039
Hyperdynamic left ventricle 21.17 12.01 7 25199 396 79718786
Palpitations 20.62 12.01 87 25119 126523 79592659
Pericarditis 20.53 12.01 4 25202 104232 79614950
Completed suicide 20.22 12.01 140 25066 245627 79473555
Product use in unapproved indication 20.08 12.01 30 25176 250329 79468853
Anhedonia 19.80 12.01 24 25182 14874 79704308
Laryngeal pain 19.76 12.01 16 25190 6098 79713084
Vasoplegia syndrome 19.71 12.01 13 25193 3617 79715565
Rhabdomyolysis 19.30 12.01 74 25132 103057 79616125
Coronary artery occlusion 19.27 12.01 24 25182 15291 79703891
Renal tubular atrophy 18.95 12.01 10 25196 1846 79717336
Oropharyngeal swelling 18.93 12.01 9 25197 1331 79717851
Unevaluable event 18.85 12.01 49 25157 55536 79663646
Myocardial ischaemia 18.81 12.01 31 25175 25488 79693694
Nodular rash 18.58 12.01 6 25200 315 79718867
Joint swelling 18.31 12.01 40 25166 288606 79430576
Wound 18.14 12.01 7 25199 116172 79603010
Cardiomegaly 18.08 12.01 31 25175 26321 79692861
Lymphomatoid papulosis 18.02 12.01 6 25200 347 79718835
Kounis syndrome 17.77 12.01 13 25193 4269 79714913
Oedema peripheral 17.50 12.01 138 25068 252150 79467032
Reaction to excipient 17.48 12.01 9 25197 1580 79717602
Febrile neutropenia 17.28 12.01 29 25177 230970 79488212
Gastrointestinal haemorrhage 17.13 12.01 92 25114 147627 79571555
Atrial fibrillation 17.03 12.01 114 25092 197772 79521410
Pancreatitis 16.99 12.01 54 25152 68521 79650661
Gastritis 16.99 12.01 43 25163 47950 79671232
Pancytopenia 16.28 12.01 17 25189 165728 79553454
Musculoskeletal stiffness 16.04 12.01 19 25187 174989 79544193
Product use issue 16.01 12.01 26 25180 209796 79509386
Hypertensive heart disease 15.73 12.01 12 25194 4194 79714988
Gastrooesophageal reflux disease 15.72 12.01 70 25136 104176 79615006
Therapeutic product effect incomplete 15.72 12.01 13 25193 141632 79577550
General physical health deterioration 15.20 12.01 41 25165 275197 79443985
Ischaemic cardiomyopathy 14.72 12.01 15 25191 7680 79711502
Blood urea increased 14.52 12.01 41 25165 48749 79670433
Cerebral infarction 14.21 12.01 39 25167 45637 79673545
Swelling face 14.07 12.01 52 25154 71160 79648022
Drug interaction 13.78 12.01 76 25130 415107 79304075
Pharyngeal oedema 13.69 12.01 21 25185 16251 79702931
Tendon rupture 13.68 12.01 18 25188 12108 79707074
Hypotension 13.65 12.01 205 25001 440112 79279070
Glossodynia 13.42 12.01 8 25198 103329 79615853
Loss of personal independence in daily activities 13.24 12.01 8 25198 102572 79616610
Electrocardiogram QT prolonged 13.22 12.01 6 25200 90380 79628802
Kidney fibrosis 13.04 12.01 10 25196 3525 79715657
Neck injury 12.82 12.01 9 25197 2772 79716410
Coronary artery surgery 12.75 12.01 4 25202 191 79718991
Dehydration 12.68 12.01 127 25079 248060 79471122
Carotid artery disease 12.03 12.01 8 25198 2256 79716926

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C09AA07 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, PLAIN
ACE inhibitors, plain
ATC C09BA07 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and diuretics
ATC C09BB13 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and calcium channel blockers
FDA MoA N0000000181 Angiotensin-converting Enzyme Inhibitors
FDA EPC N0000175562 Angiotensin Converting Enzyme Inhibitor
CHEBI has role CHEBI:35457 ACE inhibitor
CHEBI has role CHEBI:50266 Prodrugs
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
FDA PE N0000178477 Decreased Blood Pressure

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure off-label use 48447003
Atrial fibrillation off-label use 49436004 DOID:0060224
Diabetic renal disease off-label use 127013003
Acute scleroderma renal crisis off-label use 236503001
Diastolic heart failure off-label use 418304008 DOID:9775
Hypertension due to Scleroderma off-label use
Nondiabetic Proteinuric Nephropathy off-label use
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Jaundice contraindication 18165001
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Angioedema contraindication 41291007 DOID:1558
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Hepatic failure contraindication 59927004
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Chronic idiopathic constipation contraindication 82934008
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Disorder of connective tissue contraindication 105969002 DOID:65
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Azotemia contraindication 445009001
Intestinal Angioedema contraindication
Head and Neck Angioedema contraindication
Hemodialysis with High-Flux Membrane contraindication
Severe Aortic Valve Stenosis contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

ProductApplicantIngredients
Cardalis Ceva Sante Animale 2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.9 acidic
pKa2 5.34 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR IC50 6.51 WOMBAT-PK CHEMBL
Angiotensin-converting enzyme Enzyme IC50 8.70 CHEMBL
Angiotensin-converting enzyme Enzyme IC50 8.77 CHEMBL

External reference:

IDSource
4020817 VUID
N0000148336 NUI
D00620 KEGG_DRUG
86541-74-4 SECONDARY_CAS_RN
1546196 RXNORM
C0053091 UMLSCUI
CHEBI:3011 CHEBI
CHEBI:88200 CHEBI
CHEMBL838 ChEMBL_ID
CHEMBL1694 ChEMBL_ID
DB00542 DRUGBANK_ID
C044946 MESH_SUPPLEMENTAL_RECORD_UI
5362124 PUBCHEM_CID
6374 IUPHAR_LIGAND_ID
C052133 MESH_SUPPLEMENTAL_RECORD_UI
6129 INN_ID
UDM7Q7QWP8 UNII
DB14125 DRUGBANK_ID
1267 MMSL
4251 MMSL
48720 MMSL
d00730 MMSL
108572003 SNOMEDCT_US
108573008 SNOMEDCT_US
372511001 SNOMEDCT_US
C0105523 UMLSCUI
CHEMBL1192519 ChEMBL_ID
4020025 VANDF
4020817 VANDF
6128 INN_ID
86541-78-8 SECONDARY_CAS_RN
5463984 PUBCHEM_CID
6375 IUPHAR_LIGAND_ID
JRM708L703 UNII
003597 NDDF
003598 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0364 CAPSULE 20 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0364 CAPSULE 20 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0364 CAPSULE 20 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0379 CAPSULE 40 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0379 CAPSULE 40 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0379 CAPSULE 40 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0405 CAPSULE 10 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0405 CAPSULE 10 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0405 CAPSULE 10 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0406 CAPSULE 20 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0406 CAPSULE 20 mg ORAL NDA 31 sections
Lotrel HUMAN PRESCRIPTION DRUG LABEL 2 0078-0406 CAPSULE 20 mg ORAL NDA 31 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0211 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0211 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0211 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0211 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0236 TABLET, FILM COATED 5 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0236 TABLET, FILM COATED 5 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0236 TABLET, FILM COATED 5 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0236 TABLET, FILM COATED 5 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0277 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0277 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0277 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0277 TABLET, FILM COATED 20 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0325 TABLET, FILM COATED 10 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0325 TABLET, FILM COATED 10 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0325 TABLET, FILM COATED 10 mg ORAL ANDA 22 sections
Benazepril Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0185-0325 TABLET, FILM COATED 10 mg ORAL ANDA 22 sections
benazepril hydrochloride and hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0574-0227 TABLET 10 mg ORAL NDA authorized generic 23 sections
benazepril hydrochloride and hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0574-0227 TABLET 10 mg ORAL NDA authorized generic 23 sections